BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?

ABSTRACT: Vaccination against an airborne pathogen is very effective if it induces also the development of mucosal antibodies that can protect against infection. The mRNA-based vaccine encoding SARS-CoV-2 full-length spike protein (BNT162b2, Pfizer/BioNTech) protects also against infection despite being administered systemically. Here, we show that upon vaccination cognate IgG molecules are also found in the saliva, and are more abundant in SARS-CoV-2 previously exposed subjects, paralleling the development of serum IgG. The antibodies titer declines at 3 months from vaccination. We identified a concentration of specific IgG in the plasma above which the relevant IgG can be detected in the saliva. Regarding IgA antibodies, we found only protease-susceptible IgA1 antibodies in plasma while they were

SUBMITTER: Prof. Maria Rescigno 

PROVIDER: S-SCDT-EMM-2021-15326 | biostudies-other |

REPOSITORIES: biostudies-other